OncoPPi-informed discovery of Mitogen-Activated Protein Kinase Kinase 3 as a novel binding partner of c-Myc
暂无分享,去创建一个
Margaret A. Johns | Fadlo R. Khuri | Yuhong Du | Haian Fu | Xiu-Lei Mo | Qiankun Niu | F. Khuri | E. Prochownik | H. Fu | Yuhong Du | A. Ivanov | Xiulei Mo | Yifeng Wang | Qiankun Niu | Edward V. Prochownik | Andrei A. Ivanov | Valentina Gonzalez-Pecchi | Layla F. Khuri | Yifeng Wang | Yiran Xu | Yan Bai | Yan Bai | Valentina Gonzalez-Pecchi | Yiran Xu
[1] K. Tomczak,et al. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge , 2015, Contemporary oncology.
[2] Anti‐proliferative effects of γ‐tocotrienol are associated with suppression of c‐Myc expression in mammary tumour cells , 2015, Cell proliferation.
[3] Yutaka Kodama,et al. Bimolecular fluorescence complementation (BiFC): a 5-year update and future perspectives. , 2012, BioTechniques.
[4] I. Jurisica,et al. Identifying Myc interactors. , 2013, Methods in molecular biology.
[5] H. Li,et al. USP37 directly deubiquitinates and stabilizes c-Myc in lung cancer , 2014, Oncogene.
[6] Mingming Jia,et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer , 2014, Nucleic Acids Res..
[7] W. Tansey,et al. Proteolytic control of the oncoprotein transcription factor Myc. , 2011, Advances in cancer research.
[8] H. Saito,et al. Conserved docking site is essential for activation of mammalian MAP kinase kinases by specific MAP kinase kinase kinases. , 2005, Molecular cell.
[9] TylerZARUBIN,et al. Activation and signaling of the p38 MAP kinase pathway , 2005 .
[10] Benito Munoz,et al. Towards patient-based cancer therapeutics , 2010, Nature Biotechnology.
[11] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[12] Elias Campo Guerri,et al. International network of cancer genome projects , 2010 .
[13] G. Liao,et al. Regulation of c-Myc protein stability by proteasome activator REGγ , 2014, Cell Death and Differentiation.
[14] C. Sander,et al. Systematic identification of cancer driving signaling pathways based on mutual exclusivity of genomic alterations , 2014 .
[15] Thomas D. Schmittgen,et al. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.
[16] Martin Blackledge,et al. Structure and dynamics of the MKK7–JNK signaling complex , 2015, Proceedings of the National Academy of Sciences.
[17] E. Wagner,et al. Signal integration by JNK and p38 MAPK pathways in cancer development , 2009, Nature Reviews Cancer.
[18] A. Garufi,et al. Targeting MKK3 as a novel anticancer strategy: molecular mechanisms and therapeutical implications , 2015, Cell Death and Disease.
[19] Stephen K. Burley,et al. X-Ray Structures of Myc-Max and Mad-Max Recognizing DNA Molecular Bases of Regulation by Proto-Oncogenic Transcription Factors , 2003, Cell.
[20] D. Goss,et al. Thermodynamics of protein-protein interactions of cMyc, Max, and Mad: effect of polyions on protein dimerization. , 2006, Biochemistry.
[21] A. Cuadrado,et al. Mechanisms and functions of p38 MAPK signalling. , 2010, The Biochemical journal.
[22] Lee A. D. Cooper,et al. The OncoPPi network of cancer-focused protein–protein interactions to inform biological insights and therapeutic strategies , 2017, Nature Communications.
[23] M. Eilers,et al. Transcriptional regulation and transformation by Myc proteins , 2005, Nature Reviews Molecular Cell Biology.
[24] E. Prochownik,et al. Perturbation of the c-Myc-Max protein-protein interaction via synthetic α-helix mimetics. , 2015, Journal of medicinal chemistry.
[25] S. Lorenz,et al. Cdc28 kinase activity regulates the basal transcription machinery at a subset of genes , 2012, Proceedings of the National Academy of Sciences.
[26] Xiao-xin Sun,et al. The nucleolar ubiquitin-specific protease USP36 deubiquitinates and stabilizes c-Myc , 2015, Proceedings of the National Academy of Sciences.
[27] S. Oliviero,et al. PIM1-dependent phosphorylation of Histone H3 at Serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation. , 2007 .
[28] Charles Y. Lin,et al. Transcriptional Amplification in Tumor Cells with Elevated c-Myc , 2012, Cell.
[29] C. Marshall,et al. Nuclear export of the stress-activated protein kinase p38 mediated by its substrate MAPKAP kinase-2 , 1998, Current Biology.
[30] Javier León,et al. Myc and cell cycle control. , 2015, Biochimica et biophysica acta.
[31] S. Rodig,et al. Altered Subcellular Localization of c-Myc Protein Identifies Aggressive B-cell Lymphomas Harboring a c-MYC Translocation , 2010, The American journal of surgical pathology.
[32] John S Lazo,et al. Low molecular weight inhibitors of Myc–Max interaction and function , 2003, Oncogene.
[33] I. Jurisica,et al. Myc and its interactors take shape. , 2015, Biochimica et biophysica acta.
[34] Jeffrey E. Lee,et al. Measuring Protein‐Protein and Protein‐Nucleic Acid Interactions by Biolayer Interferometry , 2015, Current protocols in protein science.
[35] R. Davis,et al. Transactivation of gene expression by Myc is inhibited by mutation at the phosphorylation sites Thr-58 and Ser-62. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[36] S. Knapp,et al. Structural and Functional Characterization of the Human Protein Kinase ASK1 , 2007, Structure.